LPOXY initiates $28M Series A financing with 5 Horizons Ventures to fund pivotal trial
September 4, 2025 | Startland News Staff
PLATTE CITY, Mo. — Funding to secure the upcoming trial of a Missouri biopharmaceutical company’s solution for preventing a deadly gut infection could prove critical in the fight against a condition that claims 80 U.S. lives daily, said Dr. Larry Sutton.
LPOXY Therapeutics, which is developing a novel non-antibiotic therapy to prevent Clostridioides difficile infections (Cdiff), announced Wednesday it has signed a term sheet with 5Horizons Ventures, a life science venture capital firm focused on innovative healthcare solutions in support of a $28 million Series A financing.
Elevator pitch: LPOXY Therapeutics is transforming infection prevention with a first-in-class oral therapeutic aimed at preventing C. difficile colitis, a CDC-designated urgent public health threat that kills over 80 Americans every day. Our unique approach delivers oxygen directly to the gut, creating an environment hostile to C. difficile bacteria without using antibiotics.
The agreement facilitates the formation of an investment syndicate to fund LPOXY’s registrational STOP-Cdiff (SIDIPREV Trial On Prevention of C. difficile Infections) clinical trial.
“5 Horizons Ventures’ commitment marks a major milestone for LPOXY as we move toward launching our pivotal STOP-Cdiff trial,” said Sutton, CEO and co-founder of LPOXY, one of Startland News’ 10 Kansas City Startups to Watch in 2025. “SIDIPREV represents a novel approach to infection prevention that not only addresses a deadly unmet need but also aligns with hospital economics by reducing costly complications within fixed DRG payments.”
ICYMI: LPOXY Therapeutics punches back at gut infection (and a foe with a billion-year head start)
The upcoming trial is designed under the FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs guidance and is intended to serve as the registrational study for SIDIPREV™, a therapy that aims to prevent life-threatening Cdiff in high-risk hospitalized patients. C. difficile is categorized by the CDC as an urgent public health threat that kills 80 Americans every day.
SIDIPREV is an orally administered, enteric-coated capsule that releases a metered dose of oxygen into the lower gastrointestinal tract, creating an environment hostile to anaerobic pathogens like C. difficile. Oxygen also suppresses toxin production and has mucosal anti-inflammatory effects.
As planned, STOP-Cdiff is a randomized, placebo-controlled superiority trial that will evaluate the efficacy and safety of SIDIPREV in approximately 500 hospitalized patients at elevated risk for Cdiff due to age and antibiotic exposure. LPOXY aims to launch the trial in Q3 2026 and file for approval in 2029.
“We’re impressed by the LPOXY team, their data, and their clear-eyed strategy for succeeding where many anti-infective programs have struggled,” said Paul Ferguson, partner and CFO of 5 Horizons Ventures. “SIDIPREV avoids the reimbursement and resistance-related hurdles that have plagued traditional antibiotics, making this a rare opportunity to unlock real economic value for patients, hospitals, and investors.”
LPOXY is actively building its investment syndicate and is in discussions with other institutional investors aligned with its late-stage clinical strategy.
2025 Startups to Watch
stats here
Related Posts on Startland News
Help from above: Why protecting satellites from cyber attacks could hold key to adapting to climate change
Humans must responsibly rise to the occasion as Earth’s climate changes, Charles Beames said, detailing the role well-protected satellites and space systems can play in putting life-preserving solutions into orbit. “Space systems are one of the keys to the future, our future, of dealing with the changing climate and our adaptation,” said Beames, aerospace expert and…
In the field: Industry-specific, hands-free voice tech helps ‘hero up’ data collecting workers
After years of research, Bruce Rasa and his team identified a consistent pain point for field workers: capturing data on-the-go and looping it back to their headquarters. They need a co-pilot, he said, noting the role played by KC-based Dexer (formerly AgVoice), agriculture’s first handsfree data capture service to help cross-industry specialists create records —…
New city flag designed for KC’s now (and tomorrow): Here’s where you’ll see it flying first
Kansas City is ushering in an era of growth and development, Jared Horman said, and the unveiling of a new municipal flag is just the way to recognize this new chapter. “The timing feels particularly exciting with the Chiefs headed to the Super Bowl, the opening of the new terminal at the airport and the…
Pushing without force: Founder credits accelerator’s collaborative ‘in the trenches’ guidance for overseas scaling success
Editor’s note: This article is sponsored by the NMotion startup accelerator, but was independently produced by Startland News. The powerhouse mix of global and localized support David Biga received from the NMotion Growth Accelerator was well worth the program’s required exchange of equity, the proptech startup founder detailed. Particle Space — one of Startland News’…